Occlude Defect ,
To provide global doctors and patients with safe and innovate medical devices to treat cardiovascular diseases
Being an innovative company, we consistently explore new idea and methods
Recently, the LAmbre? Left Atrial Appendage Closure (LAAC) Master Session was successfully held by LifeTech Scientific Corporation. Thirteen well-known cardiovascular experts gathered online to share their clinical experience with the LAmbre? LAAC system.
Recently, the third session of the seminar tour-Guangdong Stop was kicked-off to provide the guidance on the standardization of the LAAC during the COVID-19 outbreak for cardiovascular doctors.
Recently, the Global Webinar-VSD Closure with KONAR-MF? Multifunctional Occluder organized by Lifetech was successfully held.
LifeTech Scientific Corporation (the “Company”) and its subsidiaries (the “Group”) announced the unaudited consolidated results for the six months ended 30 June 2020 (the “Reporting Period”)
30th March, 2020,LifeTech Scientific Corporation (the “Company”) and its subsidiaries (the “Group”) announced the audited consolidated results for the year ended 31 December 2019 (the “Reporting Period”)
LifeTech Scientific Corporation announced that it had entered into the Agreement with the wholly-owned subsidiary of China Everbright Limited, agreed to purchase, with funding to be provided by the Company, and the Vendor conditionally agreed to sell, an aggregate of not more than 300,000,000 shares, for the purpose of the Share Award Scheme.
Lifetech is a leading developer, manufacturer and vendor of advanced minimally invasive medical devices for cardiovascular and peripheral vascular diseases and disorders.
Founded in 1999, we are now the second largest provider of congenital heart defect occluders in the world and the largest provider to BRIC countries.